Antibody-Drug Conjugates

Daiichi Sankyo and Glycotope reach agreement for “first-in-class” ADC

03-Aug-2018 By Maggie Lynch

Daiichi Sankyo and Glycotope have signed a licensing agreement to develop an antibody-drug conjugate that enables tumor-specific binding to TA-MUC1.

ADC Bio: Biotech may 'hold the key' to innovation adoption

08-Jun-2018 By Flora Southey

CDMOs need to respond to biotech innovation at an R&D level to improve efficiency in antibody-drug conjugate manufacturing, says ADC Bio.

The Golden Ticket: Sanofi, Meditope initiate research collaboration to explore bioconjugation tech

09-May-2018 By Melissa Fassbender

Sanofi has awarded Meditope Biosciences a BioLabs’ “Golden Ticket” to support the development of its bioconjugation platform and create new antibody-based therapeutic constructs.

ADC Bio’s $1.5m investment to boost antibody-drug conjugate manufacturing

01-May-2018 By Flora Southey

ADC Bio has announced receipt of a £1.14m investment it says will help reduce antibody-drug conjugate manufacturing time and costs.

Bio-Separation: Our outgoing editor looks back over 5 years

13-Apr-2018 By Dan Stanton

Biopharma-Reporter editor Dan Stanton is finally packing his buffer bag and moving upstream.

News in Brief

Abzena remodels ADC facility in Pennsylvania

28-Mar-2018 By Staff Reporter

Abzena has equipped its $5m Pennsylvania bioconjugation suite with Sartoius and GE Healthcare single-use equipment.

Xencor extends ‘plug-and-play’ deal with Selexis, signs four mAbs

28-Feb-2018 By Flora Southey

Xencor and Selexis will extend their strategic partnership with the signing of four commercial license agreements to advance XmAb bispecific antibody drug candidates.

Concurrent purification approach could cut ADC manufacture by 25%, ADC Bio

16-Feb-2018 By Dan Stanton

ADC Bio has developed a concurrent conjugation and antibody purification process, not reliant on Protein A capture resin.

ImmunoGen closing MA plant: 20 jobs to go, $20m in savings

15-Feb-2018 By Staff Reporter

ImmunoGen says it is shifting drug conjugate manufacturing and quality testing to an outsourcing model and will close its Norwood facility.

NEWS IN BRIEF

Innova Biosciences boosts Lightning-Link antibody labelling tech

17-Jan-2018 By Staff Reporter

The Sygnis subsidiary has extended its antibody labelling service to allow for scalability and bulk production of antibodies.

Glythera inks alternative antibody deal with Avacta

17-Jan-2018 By Flora Southey

Glythera has signed a licensing deal to develop drug conjugates using Avacta’s Affimer technology.

ADCs: Global service demand buoyed by approvals, WuXi

20-Dec-2017 By Dan Stanton

Antibody-drug conjugates (ADCs) are one of the “hottest areas of research” says STA Pharmaceutical and WuXi Biologics which are investing in conjugation and fill/finish capabilities in China.

Abzena ups and integrates biomanufacturing and conjugation capabilities

12-Dec-2017 By Dan Stanton

Abzena has negotiated the lease on a 50,000 square foot site in San Diego as part of a $17m remodelling of its bioproduction and conjugation facilities.

Vaccinex and Catalent team on cancer ADC development

05-Dec-2017 By Dan Stanton

The deal will see Vaccinex combine its antibody optimisation platform with Catalent’s conjugation and cell line engineering technologies.

ADC Bio: Industry unprepared for aggregation risk of next-generation ADCs

22-Nov-2017 By Dan Stanton

Antibody-drug conjugate (ADC) developers are at risk of aggregation issues caused by the hydrophobic nature of next-generation linker-payloads, says ADC Bio.